Background: Throughout the last thirty years, the occurrence of diabetes has significantly risen in low- and middle-income countries. Diabetes is associated with both micro- and macrovascular complications. For numerous people with type 2 diabetes, the use several glucose-lowering treatments can be necessary to attain good glycemic control. Oral semaglutide is the 1st GLP-1RA accessible in tablet form, potentially enhancing management intensification had GLP-1RAs and giving an alternative for cases who prefer oral glucose-lowering treatment to attain superior glycemic control. Empagliflozin, a selective sodium-glucose cotransporter 2 inhibitor (SGLT2I), decreases hyperglycemia in cases had type 2 diabetes mellitus by diminishing renal glucose reabsorption and rising urinary glucose excretion. Aim of the study: The objective of the present research is to evaluate the possible benefits of the combination of oral empagliflozin and semaglutide in the management of type 2 diabetic rats and some of its associated CVS complications. Methods: Rats have been categorized into: Group 1: control normal group. Group 2: wasn’t managed diabetic (diseased group). Group 3: was managed with oral semaglutide. Group 4: was managed with empagliflozin. Group 5: was managed with oral semaglutide and empagliflozin. Treated groups received medications for four weeks. Results: Treated groups illustrated significant enhancement in almost all measured variables and the histopathology of the myocardium at the end of the fourth week of treatment. Conclusion: Our research demonstrated that the combined treatment by oral semaglutide and empagliflozin was superior to each drug alone in improving all parameters. |
